Liégeois J, Eyrolles L, Bruhwyler J, Delarge J
Laboratory of Medicinal Chemistry, University of Liège, rue Fusch 3, Liège, B-4000, Belgium.
Curr Med Chem. 1998 Apr;5(2):77-100.
Classically, the D2 receptors formed the core of the dopamine hypothesis for schizophrenia. Recently, the dopamine D4 receptors have received particular attention in this context. This is due to the atypical antipsychotic, clozapine, which is effective in treating refractory schizophrenics without the side-effect profile of typical neuroleptics, and displays a ten-fold higher affinity for D4 compared to D2 or D3 receptors. Following various reports presenting the interest of D4 receptors in treating schizophrenia, multiple chemical developments were made. During the last five years, various structures were described with a high selectivity for D4 receptor subtype. Currently, although the first clinical report was very disappointing, the observation which support the idea that D4 might serve as a target for clozapine have significantly modified and extended the understanding of mechanism underlying atypical antipsychotic treatment of schizophrenia.
传统上,D2受体构成了精神分裂症多巴胺假说的核心。最近,多巴胺D4受体在此背景下受到了特别关注。这是因为非典型抗精神病药物氯氮平对难治性精神分裂症患者有效,且没有典型抗精神病药物的副作用,并且它对D4受体的亲和力比对D2或D3受体高十倍。在各种报告表明D4受体在治疗精神分裂症方面具有重要意义之后,人们进行了多种化学研发。在过去五年中,描述了多种对D4受体亚型具有高选择性的结构。目前,尽管首份临床报告非常令人失望,但支持D4可能作为氯氮平靶点这一观点的观察结果显著改变并扩展了对非典型抗精神病药物治疗精神分裂症潜在机制的理解。